TWST Form 4: President & COO receives 68,740 RSU award

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported a routine insider equity grant to its President and COO, Patrick John Finn. On 11/18/2025, he received 68,740 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 per share. Following this grant, he beneficially owned 334,659 shares of Twist Bioscience common stock in total.

The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, subject to his continued service. This structure ties a portion of the executive’s compensation to the company’s long-term performance and his ongoing role.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Finn Patrick John

Role President and COO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	68,740	$0.00	--

Holdings After Transaction: Common Stock — 334,659 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Patrick John

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		A		68,740(1)	A	$0	334,659	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2025 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TWST report for its President and COO?

Twist Bioscience reported that President and COO Patrick John Finn received 68,740 RSUs of common stock on 11/18/2025 at a price of $0 per share.

How many Twist Bioscience (TWST) shares does Patrick John Finn own after this transaction?

After the reported RSU grant, Patrick John Finn beneficially owned 334,659 shares of Twist Bioscience common stock.

What is the vesting schedule for Patrick John Finn’s 68,740 TWST RSUs?

The 68,740 RSUs vest over 48 months, with 1/16 of the total vesting on each quarterly anniversary of November 20, 2025, subject to continued service.

What type of security was granted in this TWST Form 4 filing?

The filing reports a grant of restricted stock units (RSUs) that settle in Twist Bioscience common stock.

Is the reported TWST insider transaction a purchase for cash?

No. The Form 4 shows an award of RSUs at $0 per share, reflecting equity compensation rather than a cash purchase.

What is Patrick John Finn’s role at Twist Bioscience (TWST)?

Patrick John Finn is reported as an officer of Twist Bioscience, serving as President and COO.